SynthesisBritish journal of cancer2015

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.

A Rowland et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.